R&D spending: $57,251,000
Percentage of revenues: 14.1%
2018 overall revenue ranking: 85Accuray (Sunnyvale, Calif.) develops, manufactures and sells radiation oncology systems for shorter, safer and smarter cancer treatment options for multiple types of cancer. One of the significant technologies that the company touts on its website is the CyberKnife, which is a precise robotic treatment that is customizable for every patient.
The CyberKnife is used for stereotactic radiosurgery and stereotactic body radiation therapy and includes dynamic tracking and motion compensation. The system, according to Accuray, enables high precise, non-surgical treatment for tumors and lesions anywhere within the body, including the prostate, lung, brain, spine, liver, pancreas and kidney. The system also offers automatic, real-time tumor tracking and motion management to give more precise treatment of a variety of cancers, reducing the therapy’s impact on quality of life.